
## Hendrika A Van Den Ham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7822331/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A critical review of methodologies used in pharmaceutical pricing policy analyses. Health Policy, 2023, 134, 104576.	1.4	3
2	Unmet Medical Need as a Driver for Pharmaceutical Sciences – A Survey Among Scientists. Journal of Pharmaceutical Sciences, 2022, 111, 1318-1324.	1.6	6
3	A comparative human rights analysis of laws and policies for adolescent contraception in Uganda and Kenya. Reproductive Health, 2022, 19, 37.	1.2	7
4	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British Journal of Clinical Pharmacology, 2021, 87, 988-1000.	1.1	19
5	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban—A European comparative drug utilization study. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 440-454.	1.2	3
6	The Current State of Snakebite Care in Kenya, Uganda, and Zambia: Healthcare Workers' Perspectives and Knowledge, and Health Facilities' Treatment Capacity. American Journal of Tropical Medicine and Hygiene, 2021, 104, 774-782.	0.6	22
7	Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia. Frontiers in Public Health, 2021, 9, 645499.	1.3	4
8	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple populationâ€based cohort studies. Pharmacoepidemiology and Drug Safety, 2021, 30, 1339-1352.	0.9	17
9	Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya. PLoS Neglected Tropical Diseases, 2021, 15, e0009702.	1.3	10
10	The Burden of Snakebite in Rural Communities in Kenya: A Household Survey. American Journal of Tropical Medicine and Hygiene, 2021, 105, 828-836.	0.6	9
11	Access to sexual and reproductive health commodities in East and Southern Africa: a cross-country comparison of availability, affordability and stock-outs in Kenya, Tanzania, Uganda and Zambia. BMC Public Health, 2020, 20, 1053.	1.2	20
12	Systematic reviews of ten pharmaceutical pricing policies – a research protocol. Journal of Pharmaceutical Policy and Practice, 2020, 13, 22.	1.1	7
13	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study. Pharmacoepidemiology and Drug Safety, 2020, 30, 1293-1320.	0.9	3
14	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A populationâ€based nested case–control study. British Journal of Clinical Pharmacology, 2020, 86, 1150-1164.	1.1	42
15	The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation. TH Open, 2020, 04, e417-e426.	0.7	10
16	Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review. BMC Health Services Research, 2019, 19, 536.	0.9	83
17	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A crossâ€national drug utilization study. British Journal of Clinical Pharmacology, 2019, 85, 2524-2539.	1.1	41
18	Barriers to Accessing Internationally Controlled Essential Medicines in Uganda: A Qualitative Study. Journal of Pain and Symptom Management, 2019, 58, 835-843.e1.	0.6	7

#	Article	IF	CITATIONS
19	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. British Journal of Clinical Pharmacology, 2017, 83, 1844-1859.	1.1	17
20	Identifying the teaching content on substandard and falsified medical products in global pharmacy education as critical public health issue. Pharmacy Education, 0, , 504-516.	0.2	1